Søgning på udtrykket 'omicron' giver 43 resultater


Dokumenter [2] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [+20]

Dokumenter [2]

Version 21 (31.5.22) Væsentlige ændringer i denne version: Opdateret mAb anbefaling på baggrund af pågående epidemi med Omicron BA.2. Tekst om lav tærskel for procalcitonin-måling og anti-mikrobiel behandling ved tocilizumab er fjernet. Vedrørende afisolering, se særskilt vejledning på vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&unid=X628E0990A178D7DEC125865D003E35B3&dbpath=/VIP/Redaktoer/130177.nsf/&windo…

Sotrovimab anbefales ikke længere til behandling af tidlig COVID-19 med Omicron BA.2

Nyt fra tidsskrifterne [+20]

Der er mere end 20 resultater, måske du vil se flere resultater her?
PLoS One Infectious Diseases
6.07.2022
…ndrome coronavirus 2 were reported in the United Kingdom, with many patients and deaths. This study aimed to see knowledge, perception, and fear among the global population towards a new variant of severe acute respiratory syndrome coronavirus 2, known as Omicron (B.1.1.529). This online cross-sectional global study was conducted during the emergence of the B.1.1.529 variant, also known as the Omicron variant. The survey was carried out from 2nd December 2021 to 3rd January 2022. The descriptive analysis wa…
Journal of the American Medical Association
5.07.2022
This modeling study estimates the excess deaths attributable to COVID-19 disease in Massachusetts during the Delta (June to December 2021) and Omicron (December 2021 to February 2022) waves.
Clinical Microbiology and Infection
2.07.2022
To describe Delta/Omicron SARS-CoV-2 variants co-infection detection and confirmation during the fifth wave of COVID-19 pandemics in France in 7 immunocompetent and epidemiologically unrelated patients.
International Journal of Infectious Diseases
2.07.2022
Despite its stringent containment measures, Hong Kong has experienced a most challenging coronavirus disease 2019 (COVID-19) wave due to the Omicron variant (Mallapaty, 2022). Implementing a citywide ‘compulsory universal testing (CUT)’ and a citywide lockdown was a subject of debate in March 2022 (South China Morning Post, 2022).
Journal of Infectious Diseases
1.07.2022
AbstractBackgroundThe epidemiological advantage of Omicron variant is evidenced by its rapid spread and the ability to outcompete prior variants. Among Omicron sub-lineages, early outbreaks were dominated by BA.1 while BA.2 has gained dominance since February 2022. The relative pathogenicity and transmissibility of BA.1 and BA.2 have not been fully defined.MethodsWe compared viral loads and clinical signs in Syrian hamsters after infection with BA.1, BA.2, or D614G variant. A competitive transmission model …
Journal of Medical Virology
30.06.2022
Journal of Medical Virology, Accepted Article.
New England Journal of Medicine
29.06.2022
New England Journal of Medicine, Ahead of Print.
New England Journal of Medicine
29.06.2022
New England Journal of Medicine, Ahead of Print.
Lancet Infectious Diseases
29.06.2022
The SARS-CoV-2 omicron (B.1.1.529) variant is highly resistant against antibody-mediated neutralisation due to many mutations in the spike (S) protein.1 Several omicron subvariants have been detected, with BA.2.12.1 (first detected in the USA) and BA.4 and BA.5 (first detected in South Africa) currently outcompeting the previously circulating BA.1 and BA.2 subvariants in several countries. The S proteins of BA.4 and BA.5, which are identical on the protein level, and BA.2.12.1 harbour unique mutations (appe…
Nature
27.06.2022
Nature Medicine, Published online: 27 June 2022; doi:10.1038/s41591-022-01911-2. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa
Clinical Infectious Diseases
23.06.2022
… vaccination status. We evaluated sensitivity and specificity of RDT on days 4-6 compared to culture.ResultsAmong 92 SARS-CoV-2 RT-PCR positive participants, all completed the initial vaccine series, 17 (18.5%) were infected with Delta and 75 (81.5%) with Omicron. Seventeen percent of participants had positive cultures beyond day 5 from symptom onset with the latest on day 12. There was no difference in time to culture conversion by variant or vaccination status. For 14 sub-study participants, sensitivity a…
Lancet Infectious Diseases
23.06.2022
We recently conducted a systematic review and meta-regression of the duration of effectiveness of primary series COVID-19 vaccination against clinical outcomes before the predominance of the omicron (B.1.1.529) SARS-CoV-2 variant.1 Here we assess the duration of vaccine protection, after a primary vaccine series and after the first booster dose, against omicron, the current predominant variant, using the same methods.1
New England Journal of Medicine
22.06.2022
New England Journal of Medicine, Ahead of Print.
Lancet Infectious Diseases
21.06.2022
The BA.1, BA.2, and BA.3 omicron subvariants of SARS-CoV-2 showed similar but substantial resistance to vaccine-induced and infection-induced serum neutralising activity.1,2 The new BA.2.12.1, BA.2.13, BA.4, and BA.5 omicron subvariants containing Leu452 substitutions show more infectious potential than BA.2.3 We examined neutralising activity against the BA.1, BA.2, BA.2.11, BA.2.12.1, BA.2.13, BA.4, and BA.5 omicron subvariants in serum from people who received BBIBP-CorV (Sinopharm) primary immunisation,…
Journal of Infectious Diseases
20.06.2022
AbstractInfection by the SARS-CoV-2 variant Omicron is usually asymptomatic or mild and appears to be poorly immunogenic at least in unvaccinated individuals. Here, we found that healthcare workers vaccinated with two doses of Sputnik V and a booster dose of ChAdOx1 mount a vigorous neutralizing-antibody response after Omicron breakthrough infection.
Journal of Infectious Diseases
20.06.2022
AbstractThe highly transmissible Omicron variant has caused high rates of breakthrough infections in those previously vaccinated with ancestral strain COVID-19 vaccines. Here, we demonstrate that a booster dose of UB-612 vaccine candidate delivered 7-9 months after primary vaccination increased neutralizing antibody levels by 131-, 61- and 49-fold against ancestral SARS-CoV-2, Omicron BA.1, and BA.2 variants, respectively. Based on the RBD protein-binding antibody responses, the UB-612 third dose booster ma…
Journal of Medical Virology
18.06.2022
Journal of Medical Virology, Accepted Article.

Aktuelle smitsomme sygdomme [+20]

Der er mere end 20 resultater, måske du vil se flere resultater her?
Medscape Infectious Diseases
5.07.2022
These variants now make up 52.3% of infections, with BA.5 accounting for 36.6% of new cases and BA.4 accounting for 15.7% of new cases, according to the latest CDC data. .
Medscape Infectious Diseases
29.06.2022
The FDA's advisers on vaccines deliberated Tuesday on what direction the agency should give drugmakers about future modifications to their COVID shots to address changes in the virus. .
Medscape Infectious Diseases
27.06.2022
Pfizer studied two potential vaccines: a 'monovalent' shot that targets only Omicron, and a 'bivalent' combination booster that adds Omicron to the original vaccine. .
Medscape Infectious Diseases
22.06.2022
The vaccine manufacturer released data on its combination vaccine in development designed to protect against Omicron-specific SARS-CoV-2 strains. .
Medscape Infectious Diseases
17.06.2022
The study is considered one of the first large-scale reports about the long-term risks of Omicron. .
Medscape Infectious Diseases
14.06.2022
The subvariants appear to be escaping immunity from vaccines and previous infections -- even other Omicron infections -- and have been causing hundreds of thousands of new COVID-19 cases in recent weeks. .
Medscape Infectious Diseases
10.06.2022
The two newest subvariants of Omicron, BA.4 and BA.5, are spreading across the US and making up a higher percentage of new cases, prompting concerns about increased transmissibility. .
Medscape Infectious Diseases
8.06.2022
Moderna releases data from a trial that evaluates the efficacy, safety, and tolerability of a new booster containing a vaccine that specifically targets the Omicron variant. .
Eurosurveillance latest updates
2.06.2022
German national surveillance data analysis shows that hospitalisation odds associated with Omicron lineage BA.1 or BA.2 infections are up to 80% lower than with Delta infection, primarily in ≥ 35-year-olds. Hospitalised vaccinated Omicron cases’ proportions (2.3% for both lineages) seemed lower than those of the unvaccinated (4.4% for both lineages). Independent of vaccination status, the hospitalisation frequency among cases with Delta seemed nearly threefold higher (8.3%) than with Omicr…
Medscape Infectious Diseases
1.06.2022
Vaccination protected patients against severe disease. A combination of three vaccine doses and past infection afforded the highest protection. .
Eurosurveillance latest updates
19.05.2022
For the period of predominance of SARS-CoV-2 Omicron variant in Slovenia, February to March 2022, we estimated mRNA vaccine effectiveness (VE) against severe acute respiratory infection (SARI) COVID-19 using surveillance data. In the most vulnerable age group comprising individuals aged 65 years and more, VE against SARI COVID-19 was 95% (95% CI: 95–96%) for those vaccinated with three doses, in comparison to 82% (95% CI: 79–84%) for those vaccinated with two doses.…
Medscape Infectious Diseases
18.05.2022
The vaccinated people who had a breakthrough case of Omicron produced antibodies that helped protect against coronavirus variants. .
Medscape Infectious Diseases
13.05.2022
A Spanish healthcare worker who had received three doses of the COVID-19 vaccine was infected twice by the virus. She had the shortest known time between SARS-CoV-2 infections to date. .
ECDC Epidemiological Update
13.05.2022
As of 12 May 2022, ECDC has reclassified Omicron sub-lineages BA.4 and BA.5 from variants of interest to variants of concern.
Medscape Infectious Diseases
6.05.2022
How different are the seemingly endless stream of emerging omicron subvariants from one another and how protected are we? .
Morbidity and Mortality Weekly Report (MMWR)
5.05.2022
This report describes the effectiveness of the COVID-19 booster vaccine in preventing infection in nursing home residents.

Nyhedsbrev

Skriv din email adresse og modtag nyheder om hjemmesiden.


© 2022 Dansk Selskab for Infektionsmedicin

CVR: 33634307

version: 2.11.0 ● design: Christian Philip Fischer

Side indlæst på 0,546 s

Cookies og privatliv